Elevation Oncology, Inc. financial data

Symbol
ELEV on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
101 Federal Street, Suite 1900, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
14ner Oncology, Inc. (to 7/19/2019)
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.73K % +228%
Debt-to-equity 49.2 % -34.9%
Return On Equity -59.7 % +42.9%
Return On Assets -40.1 % +32.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 59.1M shares +39.4%
Common Stock, Shares, Outstanding 59.1M shares +39.4%
Entity Public Float 52.8M USD +137%
Common Stock, Value, Issued 6K USD +50%
Weighted Average Number of Shares Outstanding, Basic 59.1M shares +26.2%
Weighted Average Number of Shares Outstanding, Diluted 59.1M shares +26.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 26.6M USD -24.4%
General and Administrative Expense 15.4M USD -2.03%
Operating Income (Loss) -42M USD +25%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -41.9M USD +26.2%
Income Tax Expense (Benefit) 43K USD -6.52%
Net Income (Loss) Attributable to Parent -41.9M USD +26.2%
Earnings Per Share, Basic -0.66 USD/shares +69%
Earnings Per Share, Diluted -0.66 USD/shares +69.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 48.2M USD -12.2%
Marketable Securities, Current 54.9M USD +37.4%
Assets, Current 105M USD +6.61%
Property, Plant and Equipment, Net 39K USD -42.6%
Other Assets, Noncurrent 940K USD -15.3%
Assets 106M USD +6.33%
Accounts Payable, Current 2.63M USD -27.7%
Accrued Liabilities, Current 3.3M USD -16.9%
Liabilities, Current 5.93M USD -22.1%
Liabilities 36.9M USD -1.63%
Accumulated Other Comprehensive Income (Loss), Net of Tax 128K USD
Retained Earnings (Accumulated Deficit) -230M USD -22.3%
Stockholders' Equity Attributable to Parent 69.4M USD +11.1%
Liabilities and Equity 106M USD +6.33%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.58M USD +43.1%
Net Cash Provided by (Used in) Financing Activities 30.3M USD +13905%
Net Cash Provided by (Used in) Investing Activities 20.7M USD -22.2%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 59.2M shares +39.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 41.4M USD +314%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 48.2M USD -12.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities 887K USD +66.7%
Deferred Tax Assets, Valuation Allowance 45.9M USD +30.4%
Deferred Tax Assets, Gross 45.9M USD +30.4%
Depreciation 10K USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -41.8M USD +26.1%
Deferred Tax Assets, Operating Loss Carryforwards 20.2M USD +62.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 299M USD +19.5%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 3K USD -62.5%
Share-based Payment Arrangement, Expense 3.39M USD -13.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%